Quarterly report pursuant to Section 13 or 15(d)

Collaboration and License Agreements and Supply Agreements - Summary of Recognized Revenue (Details)

v3.21.2
Collaboration and License Agreements and Supply Agreements - Summary of Recognized Revenue (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue $ 8,517 $ 17,823 $ 51,226 $ 34,444
Collaboration and License Agreements and Supply Agreements        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 8,517 17,823 51,226 34,444
Collaboration and License Agreements and Supply Agreements | Bristol-Myers Squibb Company ("BMS")        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 1,118 7,119 7,784 10,673
Collaboration and License Agreements and Supply Agreements | Merck Sharp & Dohme Corporation (“Merck”)        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 6,414 9,055 38,175 18,837
Collaboration and License Agreements and Supply Agreements | Merck KGaA, Darmstadt, Germany "EMD Serono")        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 249 1,507 2,844 4,656
Collaboration and License Agreements and Supply Agreements | Vaxcyte, Inc.        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 736 142 2,423 278
BMS Agreement and the 2018 BMS Master Services Agreement        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Revenues 1,118 7,119 7,784 10,673
BMS Agreement and the 2018 BMS Master Services Agreement | Ongoing Performance Related to Unsatisfied Performance Obligations        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Revenues   1,000   2,974
BMS Agreement and the 2018 BMS Master Services Agreement | Research and Development Services        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Revenues 249 246 762 646
BMS Agreement and the 2018 BMS Master Services Agreement | Materials Supply        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Revenues 869 5,873 7,022 7,053
2020 Merck Master Services Agreement        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 6,414 9,055 38,175 18,837
2020 Merck Master Services Agreement | Ongoing Performance Related to Unsatisfied Performance Obligations        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 3,506 6,907 30,889 13,048
2020 Merck Master Services Agreement | Research and Development Services        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 419 1,732 2,328 4,245
2020 Merck Master Services Agreement | Financing Component on Unearned Revenue        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 149 416 561 1,544
2020 Merck Master Services Agreement | Materials Supply        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 2,340   4,397  
2019 EMD Serono Supply Agreement        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 249 1,507 2,844 4,656
2019 EMD Serono Supply Agreement | Contingent Payment Earned        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue   1,000 2,000 1,000
2019 EMD Serono Supply Agreement | Research and Development Services        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 214 265 503 1,088
2019 EMD Serono Supply Agreement | Materials Supply        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 35 242 341 2,568
Supply Agreement | Vaxcyte, Inc.        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 736 142 2,423 278
Supply Agreement | Vaxcyte, Inc. | Research and Development Services        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 247   716  
Supply Agreement | Vaxcyte, Inc. | Materials Supply        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue $ 489 $ 142 $ 1,707 $ 278